ClinicalTrials.gg
CompletedNCT04349072VALOR-HCMUpdated May 23, 2025Results posted

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

A Phase 3 interventional study of Mavacamten and Placebo in HOCM, Hypertrophic Obstructive Cardiomyopathy, sponsored by Bristol-Myers Squibb. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.

Enrollment
7th of 21
112 · median 75
Started
2020
the only one that year
Phase 3
6 of 21
none open now
Registered
8th of 21
by date
Lead sponsor
10 of 21
Bristol-Myers Squibb

Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 6 in phase 3, and was the 8th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MYK-461

MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multi-center study in the United States (U.S.) that will evaluate the effect of mavacamten treatment on reducing the number of septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive hypertrophic cardiomyopathy (oHCM [also known as HOCM]) who are eligible for SRT based on ACCF/AHA 2011 and/or ESC 2014 guidelines.

03

Conditions studied

  • HOCM, Hypertrophic Obstructive Cardiomyopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • At least 18 years old at screening and body weight > 45 kg at screening
  • Diagnosed with oHCM consistent with current ACCF/AHA 2011 and meet their recommendations for invasive therapies
  • Referred or under active consideration within the past 12 months for SRT procedure and willing to have SRT procedure
  • Has documented (LVEF) ≥ 60% at Screening
  • Has documented oxygen saturation at rest ≥ 90% at Screening

Key Exclusion Criteria:

  • Persistent or permanent atrial fibrillation and subject not on anticoagulation for ≥ 4 weeks prior to screening and/or not adequately rate controlled ≤ 6 months prior to screening
  • Previously treated with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation [ASA])
  • For individuals on beta blockers, calcium channel blockers, or disopyramide, any dose adjustment of these medications \< 14 days prior to screening or an anticipated change in regimen during the first 16 weeks of the study
  • Any medical condition that precludes upright exercise stress testing
  • Paroxysmal, intermittent atrial fibrillation with atrial fibrillation present at screening
  • Prior treatment with cardiotoxic agents, such as doxorubicin or similar
  • Has a history or evidence of any other disorder, condition, or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Drug: Mavacamten

    Mavacamten Capsules Other names: MYK-461

    Drug: Mavacamten

  • Placebo comparator
    Drug: Placebo

    Matching Placebo Capsules

    Drug: Placebo

Interventions

  • Mavacamten Capsules Other names: MYK-461

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16

    Participants who decided to proceed with SRT or were eligible for SRT at week 16. Participants with missing assessments were classified as meeting the primary endpoint (did not improve). SRT eligibility using the New York Heart Association Functional Class (NYHA) and left ventricular outflow tract (LVOT) assessments per the 2011 ACCF/AHA guideline clinical and hemodynamic criterion are below: * NYHA Class III or IV/ NYHA Class II with exertion-induced syncope/near syncope, AND * Dynamic LVOT gradient at rest or with provocation \>= 50 mmHg. NYHA Class II at week 16, the following rules will be applied: * NYHA Class II with history of exertional syncope/ syncope at baseline and at W16 is still NYHA Class II, they remain SRT eligible IF their maximal LVOT gradient is ≥ 50mmHg * NYHA Class III/IV at baseline and at W16 has improved to Class II, they are no longer SRT eligible UNLESS they have AE of exertional syncope or pre-syncope during the 16 weeks.

    Time frame: Week 16

Secondary outcomes

  1. Number of Participants With at Least One Class Improvement From Baseline in New York Heart Association (NYHA) Class at Week 16

    The NYHA functional classification of heart failure assigns participants to 1 of 4 categories based on the participants symptoms. Baseline values are defined generally as the last available value before the first administration of study drug of analysis interest. Participants with missing NYHA class assessments are treated as no improvement. Class 1: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class 2: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class 3: Marked limitation of physical activity. Comfortable at rest. Less-than ordinary-activity causes fatigue, palpitation, or dyspnea. Class 4: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

    Time frame: Baseline and week 16

  2. Change From Baseline to Week 16 in Kansas City Cardiomyopathy Questionnaire 23-item Version, Clinical Summary Score (KCCQ-23, CSS)

    The KCCQ-23 is a 23-item, self-administered questionnaire that measures the impact of a participant's cardiovascular disease or its treatment on 6 distinct domains using a 2-week recall period: symptoms/signs, physical limitation, quality of life (QoL), social limitations, self-efficacy, and symptom stability. The KCCQ 23 Clinical Summary Score (CSS) is derived from the Total Symptom Score (TSS) and the Physical Limitations (PL) score of the KCCQ 23. The CSS, TSS, and the PL score range from 0 to 100 with higher scores representing less severe symptoms and/or physical limitations. The CSS is a mean of the TSS and the PL score.

    Time frame: Baseline and week 16

  3. Change From Baseline to Week 16 in N-Terminal Pro-b-Type Natriuretic Peptide (NT-proBNP)

    A geometric mean ratio was used to assess the change from baseline to Week 16 in N-Terminal Pro-b-Type Natriuretic Peptide (NT-proBNP). Baseline values are defined as the last non-missing value prior to the first dose of study drug unless specified otherwise.

    Time frame: Baseline and week 16

  4. Change From Baseline to Week 16 in Cardiac Troponin

    A geometric mean ratio was used to assess the change from baseline to week 16 in cardiac troponin. Baseline values are defined as the last non-missing value prior to the first dose of study drug unless specified otherwise.

    Time frame: Baseline and week 16

  5. Change From Baseline to Week 16 in Post-Exercise Left Ventricular Outflow Tract (LVOT) Gradient

    Change from baseline to week 16 in post-exercise left ventricular outflow tract (LVOT) gradient. Baseline values are defined as the last non-missing value prior to the first dose of study drug unless specified otherwise.

    Time frame: Baseline and week 16

07

Results

Posted Mar 7, 2023

Participant flow

Randomization Period
Participant flow — Randomization Period
MilestoneMavacamtenPlacebo to Mavacamten
Started5656
Completed5655
Not completed01
Double Blind Treatment Period
Participant flow — Double Blind Treatment Period
MilestoneMavacamtenPlacebo to Mavacamten
Started5655
Completed5245
Not completed410
Long Term Follow up
Participant flow — Long Term Follow up
MilestoneMavacamtenPlacebo to Mavacamten
Started5652
Completed5142
Not completed510

Outcome measures

PrimaryComposite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16

Participants who decided to proceed with SRT or were eligible for SRT at week 16. Participants with missing assessments were classified as meeting the primary endpoint (did not improve). SRT eligibility using the New York Heart Association Functional Class (NYHA) and left ventricular outflow tract (LVOT) assessments per the 2011 ACCF/AHA guideline clinical and hemodynamic criterion are below: * NYHA Class III or IV/ NYHA Class II with exertion-induced syncope/near syncope, AND * Dynamic LVOT gradient at rest or with provocation \>= 50 mmHg. NYHA Class II at week 16, the following rules will be applied: * NYHA Class II with history of exertional syncope/ syncope at baseline and at W16 is still NYHA Class II, they remain SRT eligible IF their maximal LVOT gradient is ≥ 50mmHg * NYHA Class III/IV at baseline and at W16 has improved to Class II, they are no longer SRT eligible UNLESS they have AE of exertional syncope or pre-syncope during the 16 weeks.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16
ParticipantsMavacamtenPlacebo to Mavacamten
Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 161043
Statistical analysis
  • Mavacamten vs Placebo to Mavacamten · Cochran-Mantel-Haenszel · p = <0.0001 · Proportion difference: 58.93 · 95% CI 43.989 to 73.868
SecondaryNumber of Participants With at Least One Class Improvement From Baseline in New York Heart Association (NYHA) Class at Week 16

The NYHA functional classification of heart failure assigns participants to 1 of 4 categories based on the participants symptoms. Baseline values are defined generally as the last available value before the first administration of study drug of analysis interest. Participants with missing NYHA class assessments are treated as no improvement. Class 1: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class 2: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class 3: Marked limitation of physical activity. Comfortable at rest. Less-than ordinary-activity causes fatigue, palpitation, or dyspnea. Class 4: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

Time frame:
Baseline and week 16
Reported as:
Count of participants · Participants
Number of Participants With at Least One Class Improvement From Baseline in New York Heart Association (NYHA) Class at Week 16
ParticipantsMavacamtenPlacebo to Mavacamten
Number of Participants With at Least One Class Improvement From Baseline in New York Heart Association (NYHA) Class at Week 163512
Statistical analysis
  • Mavacamten vs Placebo to Mavacamten · Cochran-Mantel-Haenszel · p = <0.0001 · Proportion difference: 41.07 · 95% CI 24.481 to 57.662
SecondaryChange From Baseline to Week 16 in Kansas City Cardiomyopathy Questionnaire 23-item Version, Clinical Summary Score (KCCQ-23, CSS)

The KCCQ-23 is a 23-item, self-administered questionnaire that measures the impact of a participant's cardiovascular disease or its treatment on 6 distinct domains using a 2-week recall period: symptoms/signs, physical limitation, quality of life (QoL), social limitations, self-efficacy, and symptom stability. The KCCQ 23 Clinical Summary Score (CSS) is derived from the Total Symptom Score (TSS) and the Physical Limitations (PL) score of the KCCQ 23. The CSS, TSS, and the PL score range from 0 to 100 with higher scores representing less severe symptoms and/or physical limitations. The CSS is a mean of the TSS and the PL score.

Time frame:
Baseline and week 16
Reported as:
Mean · Score on a scale
Change From Baseline to Week 16 in Kansas City Cardiomyopathy Questionnaire 23-item Version, Clinical Summary Score (KCCQ-23, CSS)
Score on a scaleMavacamtenPlacebo to Mavacamten
Change From Baseline to Week 16 in Kansas City Cardiomyopathy Questionnaire 23-item Version, Clinical Summary Score (KCCQ-23, CSS)10.4 ± 16.061.8 ± 12.01
Statistical analysis
  • Mavacamten vs Placebo to Mavacamten · Mixed Models Analysis · p = <0.0001 · Leat square mean of treatment difference: 9.45 · 95% CI 4.868 to 14.041Mixed model with repeated measure (MMRM)
SecondaryChange From Baseline to Week 16 in N-Terminal Pro-b-Type Natriuretic Peptide (NT-proBNP)

A geometric mean ratio was used to assess the change from baseline to Week 16 in N-Terminal Pro-b-Type Natriuretic Peptide (NT-proBNP). Baseline values are defined as the last non-missing value prior to the first dose of study drug unless specified otherwise.

Time frame:
Baseline and week 16
Reported as:
Geometric mean · ng/L
Change From Baseline to Week 16 in N-Terminal Pro-b-Type Natriuretic Peptide (NT-proBNP)
ng/LMavacamtenPlacebo to Mavacamten
Change From Baseline to Week 16 in N-Terminal Pro-b-Type Natriuretic Peptide (NT-proBNP)0.35 ± NA1.13 ± NA
Statistical analysis
  • Mavacamten vs Placebo to Mavacamten · Mixed Models Analysis · p = <0.0001 · Mean ratio: 0.33 · 95% CI 0.266 to 0.421Mixed model with repeated measure (MMRM)
SecondaryChange From Baseline to Week 16 in Cardiac Troponin

A geometric mean ratio was used to assess the change from baseline to week 16 in cardiac troponin. Baseline values are defined as the last non-missing value prior to the first dose of study drug unless specified otherwise.

Time frame:
Baseline and week 16
Reported as:
Geometric mean · ng/L
Change From Baseline to Week 16 in Cardiac Troponin
ng/LMavacamtenPlacebo to Mavacamten
Change From Baseline to Week 16 in Cardiac Troponin0.50 ± NA1.03 ± NA
Statistical analysis
  • Mavacamten vs Placebo to Mavacamten · Mixed Models Analysis · p = <0.0001 · Mean ratio: 0.53 · 95% CI 0.406 to 0.700Mixed model with repeated measure (MMRM)
SecondaryChange From Baseline to Week 16 in Post-Exercise Left Ventricular Outflow Tract (LVOT) Gradient

Change from baseline to week 16 in post-exercise left ventricular outflow tract (LVOT) gradient. Baseline values are defined as the last non-missing value prior to the first dose of study drug unless specified otherwise.

Time frame:
Baseline and week 16
Reported as:
Mean · mmHg
Change From Baseline to Week 16 in Post-Exercise Left Ventricular Outflow Tract (LVOT) Gradient
mmHgMavacamtenPlacebo to Mavacamten
Change From Baseline to Week 16 in Post-Exercise Left Ventricular Outflow Tract (LVOT) Gradient-39.1 ± 36.51-1.8 ± 28.82
Statistical analysis
  • Mavacamten vs Placebo to Mavacamten · ANCOVA · p = <0.0001 · Leat square mean of treatment difference: -37.2 · 95% CI -48.08 to -26.24

Adverse events

Collected over Other (Not including Serious) Adverse Events (AEs) and Serious Adverse Events (SAEs) are collected from first dose to 56 days post last dose (Up to approximately 146 weeks). Participants were assessed for All-cause mortality from their date of randomization to study completion (Up to approximately 46 months.). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mavacamten1/108 (0.9%)21/108 (19.4%)96/108 (88.9%)
Placebo0/56 (0%)1/55 (1.8%)20/55 (36.4%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventMavacamtenPlacebo
Atrial fibrillationCardiac disorders4/1080/55
COVID-19Infections and infestations2/1080/55
SyncopeNervous system disorders2/1080/55
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/1080/55
Alcohol poisoningInjury, poisoning and procedural complications0/1081/55
Acute left ventricular failureCardiac disorders1/1080/55
Acute myocardial infarctionCardiac disorders1/1080/55
ArrhythmiaCardiac disorders1/1080/55
BradycardiaCardiac disorders1/1080/55
Cardiac failure acuteCardiac disorders1/1080/55
Most frequent other events
Showing 10 of 29
Most frequent other events
EventMavacamtenPlacebo
COVID-19Infections and infestations39/1082/55
FatigueGeneral disorders18/1082/55
DizzinessNervous system disorders16/1083/55
Upper respiratory tract infectionInfections and infestations15/1080/55
Urinary tract infectionInfections and infestations15/1081/55
PalpitationsCardiac disorders14/1082/55
Atrial fibrillationCardiac disorders13/1080/55
ArthralgiaMusculoskeletal and connective tissue disorders13/1080/55
Ejection fraction decreasedInvestigations12/1080/55
HeadacheNervous system disorders11/1085/55

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MavacamtenPlacebo to MavacamtenTotal
Mean59.8 ± 14.1860.9 ± 10.5560.3 ± 12.45
Sex: Female, Male
Sex: Female, Male(Participants)MavacamtenPlacebo to MavacamtenTotal
Female272855
Male292857
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MavacamtenPlacebo to MavacamtenTotal
Hispanic or Latino011
Not Hispanic or Latino5654110
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MavacamtenPlacebo to MavacamtenTotal
American Indian or Alaska Native011
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American303
White4852100
More than one race000
Unknown or Not Reported336
08

Study locations

21 sites
  • Local Institution - 0009
    Los Angeles, California 90027, United States
  • Local Institution - 0011
    Stanford, California 94305 5406, United States
  • Local Institution - 0001
    New Haven, Connecticut 06520, United States
  • Local Institution - 0021
    Weston, Florida 33331, United States
  • Local Institution - 0016
    Boston, Massachusetts 02114-2696, United States
  • Local Institution - 0007
    Boston, Massachusetts 02115, United States
  • Local Institution - 0006
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 0013
    Grand Rapids, Michigan 49503, United States
  • Local Institution - 0015
    Rochester, Minnesota 55905, United States
  • Local Institution - 0005
    Saint Louis, Missouri 63110, United States
  • Local Institution - 0010
    New York, New York 10016, United States
  • Local Institution - 0017
    Valhalla, New York 10595, United States
  • Local Institution - 0004
    Durham, North Carolina 27710, United States
  • Local Institution - 0020
    Cleveland, Ohio 44195, United States
  • Local Institution - 0002
    Portland, Oregon 97239, United States
  • Local Institution - 0003
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 0019
    Pittsburgh, Pennsylvania 15212, United States
  • Local Institution - 0014
    Nashville, Tennessee 37205, United States
  • Local Institution - 0018
    Nashville, Tennessee 37235, United States
  • Local Institution
    Houston, Texas 77030, United States
  • Local Institution - 0012
    Murray, Utah 84107-5701, United States
09

References and documents

Publications

  • Desai MY, Owens A, Geske JB, Wolski K, Saberi S, Wang A, Sherrid M, Cremer PC, Naidu SS, Smedira NG, Schaff H, McErlean E, Sewell C, Balasubramanyam A, Lampl K, Sehnert AJ, Nissen SE. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks. Circulation. 2023 Mar 14;147(11):850-863. doi: 10.1161/CIRCULATIONAHA.122.062534. Epub 2022 Nov 6. PubMed 36335531 ↗
  • Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, Cremer PC, Schaff H, McErlean E, Sewell C, Li W, Sterling L, Lampl K, Edelberg JM, Sehnert AJ, Nissen SE. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. J Am Coll Cardiol. 2022 Jul 12;80(2):95-108. doi: 10.1016/j.jacc.2022.04.048. PubMed 35798455 ↗
  • Zampieri M, Argiro A, Marchi A, Berteotti M, Targetti M, Fornaro A, Tomberli A, Stefano P, Marchionni N, Olivotto I. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. Curr Cardiol Rep. 2021 Jun 3;23(7):79. doi: 10.1007/s11886-021-01508-0. PubMed 34081217 ↗
  • Desai MY, Wolski K, Owens A, Naidu SS, Geske JB, Smedira NG, Schaff H, Lampl K, McErlean E, Sewell C, Zhang D, Edelberg JM, Sehnert AJ, Nissen SE. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. Am Heart J. 2021 Sep;239:80-89. doi: 10.1016/j.ahj.2021.05.007. Epub 2021 May 24. PubMed 34038706 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Feb 2022, 19 months.

Results were first posted in Mar 2023, 1 year 1 month after primary completion.

Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2020
First posted
Apr 16, 2020
StartActual
Jul 6, 2020
Primary completionActual
Feb 7, 2022
CompletionActual
May 20, 2024
Results first posted
Mar 7, 2023
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04349072
Responsible party
Sponsor
First posted
Apr 16, 2020
Start date
Jul 6, 2020
Primary completion
Feb 7, 2022
Completion
May 20, 2024
Results posted
Mar 7, 2023
Last update
May 23, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion